Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
ENDRA Life Sciences (NASDAQ: NDRA) announced the acceptance of a poster presentation at The Liver Meeting 2024, showcasing their TAEUS technology's capability to measure liver fat in high-BMI patients. The study demonstrates TAEUS's ability to obtain liver fat measurements in patients with BMI over 35, including cases where BMI exceeded 40 and the liver was more than 40mm below the skin surface. The presentation, titled 'Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity,' will be presented at the AASLD conference in San Diego from November 15-19, 2024.
ENDRA Life Sciences (NASDAQ: NDRA) ha annunciato l'accettazione di una presentazione sotto forma di poster a The Liver Meeting 2024, che mette in evidenza la capacità della loro tecnologia TAEUS di misurare il grasso epatico in pazienti con alto BMI. Lo studio dimostra la capacità di TAEUS di ottenere misurazioni del grasso epatico in pazienti con un BMI superiore a 35, inclusi i casi in cui il BMI superava 40 e il fegato si trovava più di 40mm sotto la superficie della pelle. La presentazione, intitolata 'Valutazione non invasiva della malattia epatica steatosica in individui con obesità di classe 2 e classe 3,' sarà presentata alla conferenza AASLD a San Diego dal 15 al 19 novembre 2024.
ENDRA Life Sciences (NASDAQ: NDRA) anunció la aceptación de una presentación en formato póster en The Liver Meeting 2024, que mostrará la capacidad de su tecnología TAEUS para medir la grasa hepática en pacientes con un alto índice de masa corporal (BMI). El estudio demuestra la habilidad de TAEUS para obtener mediciones de grasa hepática en pacientes con un BMI superior a 35, incluyendo casos donde el BMI superaba 40 y el hígado estaba a más de 40 mm debajo de la superficie de la piel. La presentación, titulada 'Evaluación no invasiva de la enfermedad hepática esteatósica en individuos con obesidad de clase 2 y clase 3,' se presentará en la conferencia AASLD en San Diego del 15 al 19 de noviembre de 2024.
ENDRA Life Sciences (NASDAQ: NDRA)는 The Liver Meeting 2024에서 포스터 발표가 수락되었다고 발표했습니다. 이 발표는 고체중지수(BMI) 환자에서 간 지방을 측정할 수 있는 TAEUS 기술의 능력을 보여줍니다. 이 연구는 BMI가 35를 초과하는 환자에서 간 지방 측정을 수행할 수 있는 TAEUS의 능력을 입증하며, 여기에는 BMI가 40을 초과하고 간이 피부 표면에서 40mm 이상 아래에 있는 경우도 포함됩니다. '2급 및 3급 비만 개인의 지방간 질환에 대한 비침습적 평가'라는 제목의 이 발표는 2024년 11월 15일부터 19일까지 샌디에이고에서 열리는 AASLD 회의에서 발표될 예정입니다.
ENDRA Life Sciences (NASDAQ: NDRA) a annoncé l'acceptation d'une présentation sous forme de poster lors de The Liver Meeting 2024, mettant en avant la capacité de sa technologie TAEUS à mesurer la graisse hépatique chez les patients ayant un IMC élevé. L'étude démontre la capacité de TAEUS à obtenir des mesures de graisse hépatique chez des patients dont l'IMC est supérieur à 35, y compris dans les cas où l'IMC dépassait 40 et où le foie était situé à plus de 40 mm sous la surface de la peau. La présentation, intitulée 'Évaluation non invasive de la maladie hépatique stéatosique chez des individus obèses de classe 2 et classe 3,' sera présentée lors de la conférence AASLD à San Diego du 15 au 19 novembre 2024.
ENDRA Life Sciences (NASDAQ: NDRA) hat die Annahme einer Posterpräsentation auf The Liver Meeting 2024 bekannt gegeben, die die Fähigkeit ihrer TAEUS-Technologie zur Messung von Leberfett bei Patienten mit hohem BMI zeigt. Die Studie belegt die Fähigkeit von TAEUS, Leberfettmessungen bei Patienten mit einem BMI über 35 zu erhalten, einschließlich der Fälle, in denen der BMI 40 übersteigt und die Leber mehr als 40 mm unter der Hautoberfläche liegt. Die Präsentation mit dem Titel 'Nicht-invasive Bewertung der steatotischen Lebererkrankung bei Personen mit Adipositas der Klassen 2 und 3' wird auf der AASLD-Konferenz in San Diego vom 15. bis 19. November 2024 präsentiert.
- TAEUS technology demonstrates capability to measure liver fat in patients with BMI over 40, where traditional point-of-care solutions struggle
- Study acceptance at AASLD, the largest worldwide scientific conference for liver diseases, validates technology's potential
- None.
“This presentation highlights the potential of our TAEUS technology to obtain liver fat fraction measurements in patients with body mass index (BMI) exceeding 35, where accurate and reliable assessment of liver fat is challenging with existing point-of-care solutions. In extreme cases, TAEUS was able to obtain valid measurements of fat fraction in subjects with BMI exceeding 40, where the liver was more than 40mm below the skin surface. The subjects in this presentation were derived from a larger study comparing the performance of TAEUS to MRI measurements of fat fraction in the liver,” stated Michael Thornton, Chief Technology Officer of ENDRA. “We are pleased this abstract was accepted for presentation at AASLD, the largest worldwide scientific conference for liver diseases. We are committed to submitting additional abstracts for presentation at medical and scientific meetings to create further awareness of the unique capabilities of our TAEUS technology in point-of-care applications.”
Publication Number: 2089
Title: Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity
Presenter: Michael
Session: Diagnostics and Biomarkers - MASH
Date: November 16, 2024
Time: 8:00am – 5:00pm Pacific Standard Time
The poster will be available on the Research and Media section of ENDRA's website after the conference ends.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) and metabolic dysfunction-associated steatohepatitis (MASH), chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112955229/en/
Company:
Richard Jacroux
Chief Financial Officer
investors@endrainc.com
www.endrainc.com
Investor Relations:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
ybriggs@allianceadvisors.com
Source: ENDRA Life Sciences Inc.
FAQ
When will ENDRA Life Sciences (NDRA) present their TAEUS liver study at AASLD 2024?
What BMI range can ENDRA's (NDRA) TAEUS technology measure liver fat?
What is the title of ENDRA Life Sciences' (NDRA) presentation at The Liver Meeting 2024?
